Sees FY23: Sacral neuromodulation revenue of $288.5 million, an increase of 30% compared to fiscal year 2022. Bulkamid revenue of $73.5 million, an increase of 42% compared to fiscal year 2022.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXNX: